Prophylaxis of candidiasis in cancer patients.
Patients undergoing therapy for metastatic malignancies were randomly assigned to receive fluconazole or placebo as antifungal prophylaxis. Oropharyngeal candidiasis developed in 28% of 54 evaluable patients receiving placebo but in only 2% of 58 evaluable patients receiving fluconazole (P = .0003). Among patients receiving placebo, oropharyngeal candidiasis (thrush) occurred in 30% of those receiving antibiotic therapy and in 44% of those receiving adrenal corticosteroid therapy. Oropharyngeal candidiasis developed in 54% of the placebo patients who were colonized by Candida sp at the onset of prophylaxis. Fluconazole proved to be effective for prophylaxis of oropharyngeal candidiasis in susceptible patients and was well tolerated.
Bodey
G P
GP
Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Samonis
G
G
Rolston
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D002180:Candidiasis, Oral / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D016032:Randomized Controlled Trials as Topic
D015725:Fluconazole